Received Jul 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | LA |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | LA |
she has not been well; not received her second dose yet; This non-serious case was reported by a consumer via call center representative and described the occurrence of unwell in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included cancer (diagnosed pre Shingrix vaccination). On 04-NOV-2024, the patient received the 1st dose of Shingrix (left arm). On an unknown date, the patient received the 2nd dose of Shingrix (left arm). On an unknown date, an unknown time after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced unwell (Verbatim: she has not been well) and incomplete course of vaccination (Verbatim: not received her second dose yet). The outcome of the unwell was not resolved and the outcome of the incomplete course of vaccination was not applicable. It was unknown if the reporter considered the unwell to be related to Shingrix. It was unknown if the company considered the unwell to be related to Shingrix. Additional Information: GSK Receipt Date: 03-JUL-2025 The patient stated that she received the first dose of Shingrix on 04 November 2024 and had not received her second dose, yet which led to incomplete course of vaccination. The patient mentioned that she had not been well due to having cancer and receiving treatment (Cancer was diagnosed pre Shingrix).
Cancer (diagnosed pre Shingrix vaccination)